Please login to the form below

Not currently logged in
Email:
Password:

Novartis to acquire Genoptix

Novartis is buy the diagnostics services company Genoptix for $470m in order to obtain technologies that will support programmes in oncology

Novartis has entered into a definitive agreement to buy the diagnostics services company Genoptix for $470m in order to obtain technologies that will support and expedite the development of companion diagnostic programmes, particularly in oncology.

Novartis said it would commence a tender offer for all outstanding shares of common stock of Genoptix for $25 per share, a premium of about 40 per cent over the company's per share closing price on December 13.

Genoptix, which provides personalised diagnostic services to haematologists and oncologists, will become part of Novartis Molecular Diagnostics, a unit of Novartis Pharmaceuticals Division.

The laboratory company specialises in diagnosing cancers in bone marrow, blood and lymph nodes. Genoptix also has a BioPharm division that supports clinical trials with haematology/oncology testing to aid in assay development, patient eligibility/stratification, efficacy endpoints, and lab results interpretation.

"The acquisition of the Genoptix medical laboratory will serve as a strong foundation for our individualised treatment programmes," said Joseph Jimenez, CEO of Novartis.

Carlsbad, California-based Genoptix was founded in 1999 and currently has about 500 employees. The company had sales of $184m in 2009 and $148m in the first nine months of 2010.

Novartis said it plans to maintain Genoptix's existing operations and continue delivering its services to community-based haematologists and oncologists. The transaction has been approved by the Genoptix Board of Directors and is expected to close in the first half of this year.

24th January 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics